Romania Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Romania Breast Cancer Therapeutics Market Analysis

$ 3999

Due to the rising prevalence of breast cancer and acceptance of new targeted therapeutics, the Romania breast cancer therapeutics market is expected to witness growth from $53 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-2030. The market is segmented by therapy, by cancer type, and by distribution channel. Antibiotice, Bristol-Myers Squibb, and Eli Lilly are the key competitors in the Romania breast cancer therapeutics market.

ID: IN10ROPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Romania AUTHOR: Parul Choudhary

Buy Now

Romania Breast Cancer Therapeutics Market Executive Analysis

The Romania breast cancer therapeutics market size is at around $53 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. Romania spent $739 per capita on healthcare in 2019. From $70 in 2000 to $739 in 2019, Romania's health spending per capita climbed at an average annual rate of 14.57%. The 2022 state budget, which estimates a cash deficit equal to 5.84% of the Gross Domestic Product (GDP) and 4.6% economic growth, was approved by the Romanian parliament. Next year, GDP is projected to increase to $301 Bn. The healthcare system in Romania requires significant investment and has some of the least developed facilities in the European Union (EU). The nation, which projects a 7.1% deficit for this year, has pledged to keep public debt levels below 50% of GDP and to gradually reduce its fiscal shortfall below the EU's 3% threshold by 2024.

Breast cancer affects about 10,000 women in Romania. This unfortunate scenario is caused by the complex aetiology of breast cancer. There are environmental and genetic influences. For BRCA1 and BRCA2 mutation carriers, the lifetime risk of breast cancer ranges from 45 to 80%. The range of BRCA1 and BRCA2 gene modifications includes frameshift, nonsense, and missense mutations that change how proteins function, as well as massive rearrangements and splice mutations that result in protein truncation. Breast cancer instances with oestrogen or progesterone receptor positivity benefit from hormonal or endocrine therapy. Both metastatic breast cancer and early-stage breast cancer are treated with hormone treatment. Cancer growth, which is triggered by hormones, is inhibited by medications like tamoxifen or aromatase inhibitors. The cancer proteins, DNA, or the tissue environment that encourages the growth of the tumour are all targets of targeted therapy. It alters the cell cycle process and is also referred to as biological treatment. The treatment is effective against specific protein receptors found in cancer cells. They aid in limiting or stifling the spread of malignancy. Along with regular surgeries, chemotherapies, and radiotherapies, the use of hormone and targeted therapies are also prevalent in Romania.

romania breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The rise in breast cancer cases in Romania, which is anticipated to have an impact on the need for novel treatments such as advanced targeted therapies for breast cancer therapeutics, is one of the factors driving the growth of the Romania breast cancer therapeutics market. Furthermore, the market is expected to rise as a result of strong immunotherapy treatment acceptance.

Market Restraints

Lack of access to more modern medications and expensive medical care are two of the major barriers to breast cancer therapeutics market expansion in Romania. Inadequate healthcare infrastructure and reimbursement rules may also hinder the growth of the Romania breast cancer therapeutics market.

Competitive Landscape

Key Players

Terapia (ROU)
Zentiva (ROU)
Sandoz (ROU)
Antibiotice (ROU)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

A list of 113 medications for cancer patients is covered by the National Oncology Program. The National Health Insurance House (CNAS) in Romania fully reimburses the cost of all included medications. The Romanian Constitution theoretically guarantees access to certain drugs. However, there is no trustworthy structure in place to proactively stop and address shortages when they do. The CNAS determines which surgeries, drugs, and therapies are covered by the national health insurance program as well as the rates at which these services are reimbursed. Depending on the type of therapy and the patient's specific circumstances, the particular payment policies for breast cancer therapy may change.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.